Persons included in the study were enrolled as New Vaccine Surveillance Network study participants (n = 1,897) and had a fecal specimen collected (n = 1,363, 72%) that was tested for norovirus and rotavirus (n = 1,295, 95%) (Technical Appendix Figure 1 ). Pentavalent rotavirus vaccine (RV5) (RotaTeq; Merck and Co. Inc., Whitehouse Station, NJ, USA) was recommended for routine use in US infants in February 2006 in children 6-32 weeks of age. Therefore, to best gauge the possible effect of rotavirus vaccination on acute gastroenteritis (AGE) in this study population, we further restricted study participants to those born on or after April 1, 2006 (n = 1,178), and who had reached the Advisory Committee on Immunization Practices-recommended age for completion of RV5 vaccine series (i.e., 8 months of age), to avoid confounding by age at time of last dose (n = 759) (1). Furthermore, only those children for whom a complete provider-verified vaccination record could be obtained were included (n = 748). Only rotavirus vaccination doses administered >14 days before AGE symptom onset were included. Study participants receiving any dose of monovalent rotavirus vaccine (Rotarix; GlaxoSmithKline Biologicals, Rixensart, Belgium) or a dose of unknown type were further excluded (n = 677). To ensure a complete severity analysis, only persons with complete severity score data were included in final analysis (n = 577). Of the remaining persons, 144 (25%) were positive for norovirus, 96 (17%) were positive for rotavirus, and 334 (58%) were negative for norovirus and rotavirus. Three persons positive for norovirus and rotavirus and were excluded from analysis.
Demographic characteristics of norovirus-positive case-patients and control patients with AGE were assessed for potential confounding of comparisons in clinical profile. Vaccine effectiveness (VE) of a full course and any dose of rotavirus vaccine were calculated at (1 -adjusted odds ratio) × 100; odds ratios were adjusted for race and insurance status on the basis of results of the analysis of demographic characteristics.
Results
Current or past breastfeeding, premature birth, household size, highest household degree, and daycare attendance did not differ between norovirus case-patients and control patients with AGE (Technical Appendix Table 1 ). However, control patients with AGE were significantly more likely to be black, non-Hispanic (p = 0.02), and use public insurance (p = 0.01) than were norovirus case-patients. These groups may have been less likely to seek care for norovirus AGE given the lower occurrence of fever compared with other causes of AGE. Despite these differences, control patients with AGE have been found to be the most appropriate control group during other New Vaccine Surveillance Network studies (2,3).
Of 144 norovirus-positive specimens, 134 (93%) could be genotyped. Of these, 89 (66%) were positive for genogroup II type 4 (GII.4). Forty-one (31%) were positive for a GII genotype other than GII.4, and 4 (3%) were positive for GI. Of the 45 non-GII.4 genotypes found, GII.12 was the most common (n = 19, 46%). Case-patients with norovirus GII.4 reported a significantly longer duration of vomiting than patients with non-GII.4 norovirus (p = 0.05), but the median overall severity score (11) for each group was the same (Technical Appendix Table 2 ).
To validate our results for vaccine effectiveness (VE) of RV5 against norovirus disease, we also calculated VE against rotavirus disease. VE of RV5 against rotavirus disease was 84% (95% CI 73%-90%) for any dose and 86% (95% CI 74% -92%) for a full course, consistent with other recent studies (2-4). Furthermore, we compared individual severity score components and overall severity scores among norovirus case-patients receiving 0, 1 or 2, or 3 doses of RV5 (Technical Appendix Figure 2 ). There were no differences in any severity score components when case-patients with norovirus receiving 3 doses of RV5 were compared with to unvaccinated case-patients with norovirus, or when norovirus case-patients receiving 1 or 2 doses were compared with unvaccinated case-patients with norovirus. Median severity scores among each of these groups of case-patients with norovirus were likewise not different. 
